{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:10:21Z","timestamp":1790349021926,"version":"4.1.0"},"reference-count":77,"publisher":"Wiley","issue":"S4","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>New treatment possibilities and modalities are now available globally for patients with haemophilia requiring surgery or invasive procedures.<\/jats:p><jats:p>The first is the appropriate application of low\u2010dose protocols of clotting factor concentrates (CFC) achieving adequate perioperative haemostasis in resources constraint environments. The increasing availability of CFC through humanitarian aid programs allows more invasive surgeries to be performed for which efficacy and safety data should be more widely collected and reported.<\/jats:p><jats:p>Second, extended half\u2010life CFC that are increasingly available in many countries represent valuable alternatives to standard half\u2010life products in surgical patients allowing reduced number of infusions and lower consumption, in particular for extended half\u2010life factor IX.<\/jats:p><jats:p>Third, in the era of recently introduced nonfactor prophylaxis, some minor surgical procedures can now be performed without additional haemostatic treatment, others with few low\u2010dose administrations of CFC or bypassing agents. Additional factor VIII\/IX or recombinant activated factor VII has proven to be safe and effective in association with emicizumab for major surgeries and it was effectively given at low doses in association with fitusiran (including activated prothrombin complex concentrate). No thrombotic complications have been reported in the surgical setting so far. A multidisciplinary team\/facility remains crucial to manage major surgery in patients on prophylaxis with these new agents.<\/jats:p>","DOI":"10.1111\/hae.14551","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T06:07:08Z","timestamp":1651817228000},"page":"93-102","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Managing invasive procedures in haemophilia patients with limited resources, extended half\u2010life concentrates or non\u2010replacement therapies in 2022"],"prefix":"10.1111","volume":"28","author":[{"given":"Maria Elisa","family":"Mancuso","sequence":"first","affiliation":[{"name":"Center for Thrombosis and Haemorrhagic Diseases IRCCS Humanitas Research Hospital  Rozzano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikant","family":"Apte","sequence":"additional","affiliation":[{"name":"Sahyadri Speciality Hospital  Pune Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Hermans","sequence":"additional","affiliation":[{"name":"Division of Haematology Haemostasis and Thrombosis Unit, Saint\u2010Luc University Hospital Universit\u00e9 catholique de Louvain (UCLouvain)  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14012"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01950.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615621"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-922225"},{"issue":"1","key":"e_1_2_6_7_1","first-page":"8","article-title":"Surgery in patients with congenital coagulation disorders","volume":"7","author":"Bhushan V","year":"1994","journal-title":"Natl Med J India"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00148.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00161.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12878-017-0080-1"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00844.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01448.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb06951.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00766.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1995.tb00089.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.11.006"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2019.08.023"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13246"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13807"},{"issue":"1","key":"e_1_2_6_20_1","first-page":"1","article-title":"Long\u2010acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A","volume":"116","author":"Mahlangu JN","year":"2016","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13112"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14426"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12972"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13041"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13557"},{"key":"e_1_2_6_26_1","article-title":"EHL\u2010FIX in haemophilia B carriers with FIX deficiency","author":"Marliere C","year":"2019","journal-title":"Haemophilia"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32722-7"},{"issue":"1","key":"e_1_2_6_28_1","first-page":"105","article-title":"Perioperative management of patients with hemophilia (PWH) receiving fitusiran prophylaxis with reduced doses of BPA or factor replacement","volume":"27","author":"Ragni MV","year":"2021","journal-title":"Haemophilia"},{"key":"e_1_2_6_29_1","first-page":"129","article-title":"Successful perioperative hemostasis use of rFVIIa in major orthopaedic surgery in a severe haemophilia B patient with inhibitors on concizumab prophylaxis","volume":"26","author":"Jim\u00e9nez Yuste V","year":"2020","journal-title":"Haemophilia"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148571"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.89.89"},{"issue":"1","key":"e_1_2_6_32_1","first-page":"115","article-title":"Surgical experience from four phase III studies (HAVEN 1\u20104) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors","volume":"3","author":"Santagostino E","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145890"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115089"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000228"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.215129"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719860025"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3401001"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16512"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001060"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14005"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2020.08.058"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14212"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03095-w"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29041"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1728667"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211040345"},{"key":"e_1_2_6_48_1","article-title":"Port removal in patients receiving emicizumab prophylaxis: a single centre experience and review of the literature","author":"Swan D","year":"2021","journal-title":"Haemophilia"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009217"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13495"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13817"},{"issue":"2","key":"e_1_2_6_57_1","first-page":"143","article-title":"Emergency management in patients with haemophilia A patinets with inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET","volume":"18","author":"Castaman G","year":"2020","journal-title":"Blood Transfus"},{"key":"e_1_2_6_58_1","unstructured":"MASAC document #258 approved on February 28 2020 retrievable at:https:\/\/www.hemophilia.org\/sites\/default\/files\/document\/files\/258_emicizumab.pdf(last access on Dec 8th 2021)"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1127-6476"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14322"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801662"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14172"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20422"},{"issue":"1","key":"e_1_2_6_64_1","first-page":"433","article-title":"Major surgery in emicizumab HAVEN 1 trial patients: the New Zealand experience","volume":"4","author":"Ockelford P","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_6_65_1","first-page":"120","article-title":"Emicizumab use in major orthopedic surgery \u2013 first experience in Slovenia, a case report","volume":"26","author":"Anzej Doma S","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"e_1_2_6_66_1","first-page":"422","article-title":"Successful management with a major trauma caused by vehicle accident in a severe hemophilia A patient with inhibitor under emicizumab treatment","volume":"3","author":"Chou SC","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16964"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13877"},{"issue":"1","key":"e_1_2_6_69_1","first-page":"584","article-title":"Surgical experience with emicizumab: a single center experience with central venous access device removal","volume":"4","author":"Badle S","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14358"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616569"},{"issue":"2","key":"e_1_2_6_72_1","first-page":"LBA","article-title":"Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia: first results from a phase 3 study to evaluate efficacy and safety in people with hemophilia A or B without inhibitors (ATLAS\u2010A\/B)","volume":"138","author":"Srivastava A","year":"2021","journal-title":"Blood"},{"key":"e_1_2_6_73_1","unstructured":"World Federation of Haemophilia.https:\/\/news.wfh.org\/global\u2010dosing\u2010hold\u2010in\u2010fitusiran\u2010trials\u2010initiated\u2010by\u2010sanofi\u2010genzyme\u2010to\u2010investigate\u2010new\u2010adverse\u2010events\/Last access on 10 Dec 2021"},{"key":"e_1_2_6_74_1","unstructured":"World Federation of Haemophilia.https:\/\/news.wfh.org\/wp\u2010content\/uploads\/Fitusiran\u2010EAHAD\u2010Media\u2010update.pdfLast access on 10 Dec 2021"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001542"},{"key":"e_1_2_6_76_1","unstructured":"National Hemophilia Foundationhttps:\/\/www.hemophilia.org\/news\/three\u2010concizumab\u2010trials\u2010halted\u2010by\u2010novo\u2010nordiskLast accessed on: 10 Dec 2021"},{"key":"e_1_2_6_77_1","unstructured":"Novo Nordisk Press Releasehttps:\/\/ml\u2010eu.globenewswire.com\/Resource\/Download\/32302d78\u2010439f\u20104a97\u2010a655\u20103f7b96e2cc76Last accessed on: 10 Dec 2021"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1692427"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14551","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T09:44:12Z","timestamp":1698831852000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":77,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/hae.14551"],"URL":"https:\/\/doi.org\/10.1111\/hae.14551","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"2022-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}